Dr. Aringer has received consulting fees and/or honoraria (less than $10,000 each) from Centocor and Schering-Plough.
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus
Version of Record online: 28 DEC 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 56, Issue 1, pages 274–279, January 2007
How to Cite
Aringer, M., Steiner, G., Graninger, W. B., Höfler, E., Steiner, C. W. and Smolen, J. S. (2007), Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis & Rheumatism, 56: 274–279. doi: 10.1002/art.22327
- Issue online: 2 JAN 2007
- Version of Record online: 28 DEC 2006
- Manuscript Accepted: 6 OCT 2006
- Manuscript Received: 15 MAR 2006
- 3Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383–90., , , , .
- 4Infliximab, but not etanercept, induces IgM anti–double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192–201., , , , , .
- 13The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451–9., , , , , , et al.